MAM
Vizeum bags media duties of VGP Universal Kingdom
MUMBAI: Vizeum India, the media communication specialist from the Dentsu Aegis Network, is riding high on success. The agency, which added Hindware and Jet Privilege to its media kitty last fortnight, has added yet another client to its roster.
The agency has been named the media AOR for VGP Universal Kingdom, a Chennai-based family amusement park.
The concept of amusement parks and beach resorts, which were only popular in foreign countries until a while back, was brought into India by VG Paneerdas in the year 1975. He created VGP Golden Beach, located on the East Coast Road in Chennai.
Currently VGP Universal Kingdom has more than 40 rides, including the first of its kind in India – the family roller coaster ride, the mixer ride, the Top Gun from all over Europe and the United States and a themed water park.
VGP Universal Kingdom managing director VGP Ravidas said, “Fun is a serious business and we have been looking for a media partner who understands this balance. We found Vizeum perfectly fitting the bill. I feel they have the right wherewithal to work with us in fulfilling our future ambitions. We look forward to a long and fruitful relationship with Vizeum.”
Vizeum managing director Indian subcontinent S Yesudas added, “We are grateful to the VGP Universal Kingdom management for finding a partner in Vizeum. We will have fun together in working on this assignment while we seriously help the park move forward in consumer engagement and growth. This business will be handled out of our Chennai office, under the leadership of Vizeum South VP Subhas Warrier.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
